Derek Overstreet

Dr. Derek Overstreet

Sonoran Biosciences (United States), Scottsdale, Arizona, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2012 in Journal of Polymer Science Part B: Polymer Physics
Verified
Journal Article
Open access
PDF file
DODerek Overstreet
Derek Overstreet
DDDipankar Dutta
Dipankar Dutta
SSSarah E. Stabenfeldt
Sarah E. Stabenfeldt
BVBrent Vernon
Brent Vernon
Hydrogels are promising for a variety of medical applications due to their high water content and mechanical similarity to natural tissues. When made injectable, hydrogels can reduce the invasiveness of application, which in turn reduces surgical and recovery costs. Key schemes used to make hydrogels injectable include in situ formation due to physical and/or chemical cross‐linking. Advances in polymer science have provided new injectable hydrogels for applications in drug delivery and tissue engineering. A number of these injectable hydrogel systems have reached the clinic and impact the health care of many patients. However, a significant remaining challenge is translating the ever‐growing family of injectable hydrogels developed in laboratories around the world to the clinic. © 2012 Wiley Periodicals, Inc. J Polym Sci Part B: Polym Phys, 2012

1 July 2016 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
PCPaulo Castaneda
Paulo Castaneda
AMAlex McLaren
Alex McLaren
GTGamuchirai Tavaziva
Gamuchirai Tavaziva
DODerek Overstreet
Derek Overstreet
Expected to cause high local levels for longer than 24 hours. It is unknown if longer antimicrobial exposures require the same concentration to eradicate bacteria in biofilm. Questions/purposes Does MBEC change with increased antimicrobial exposure time? Methods Biofilms were grown for 24 hours using five pathogens (methicillin-sensitive Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, and Pseudomonas aeruginosa) and then exposed to four antimicrobials regimens: tobramycin, vancomycin, and tobramycin combined with vancomycin in 3:1 and 1:1 ratios by weight in concentrations of 62.5, 125, 250, 500, 1000, 2000, 4000, and 8000 μg/mL for three durations, 1, 3, and 5 days, in triplicate. MBEC was measured as the lowest concentration that killed all bacteria in the biofilm determined by 21-day subculture. Results MBEC was lower when antimicrobial exposure time was longer. For the staphylococcus species, the MBEC was lower when exposure time was 5 days than 1 day in 11 of 12 antimicrobial/microorganism pairs. The MBEC range for these 11 pairs on Day 1 was 4000 to > 8000 μg/mL and on Day 5 was < 250 to 8000 μg/mL. MBEC for tobramycin/P. aeruginosa was 2000 μg/mL on Day 1 and ≤ 250 μg/mL on Day 5, and for E. coli, 125 μg/mL on Day 1 and ≤ 62.5 on Day 5. Conclusions Although antimicrobial susceptibility was lower for longer exposure times in the microorganisms we studied, confirmation is required for other pathogens. Clinical Relevance One-day MBEC assays may overestimate the local antimicrobial levels needed to kill organisms in biofilm if local levels are sustained at MBEC or above for longer than 24 hours. Future studies are needed to confirm that antimicrobial levels achieved clinically from local delivery are above the MBEC at relevant time points and to confirm that MBEC for in vitro microorganisms accurately represents MBEC of in vivo organisms in an clinical infection....

17 December 2014 in Annals of Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
JHJohn M. Heffernan
John M. Heffernan
DODerek Overstreet
Derek Overstreet
LLLong D. Le
Long D. Le
BVBrent Vernon
Brent Vernon
RSRachael W. Sirianni
Rachael W. Sirianni

1 January 2015 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
PDF file
DODerek Overstreet
Derek Overstreet
AMAlex McLaren
Alex McLaren
FCFrancis Calara
Francis Calara
BVBrent Vernon
Brent Vernon
RMRyan McLemore
Ryan McLemore
Local delivery can achieve the high antimicrobial concentrations necessary to kill biofilm-related microbes. Degradation times for resorbable carriers are too long. Hydrogels (gels of hydrophilic polymer in water) can degrade faster but release antimicrobials too quickly. We previously developed hydrogels based on the copolymer poly(N-isopropylacrylamide-co-dimethyl-γ-butyrolactone acrylate-co-Jeffamine® M-1000 acrylamide) (PNDJ) with delivery times of several days with complete degradation in less than 6 weeks. We asked: (1) What is the elution profile of gentamicin from PNDJ hydrogels? (2) Is gentamicin released from gentamicin-loaded PNDJ (G-PNDJ) hydrogel effective for treatment of orthopaedic infection? (3) Does local gentamicin delivery from G-PNDJ hydrogel cause renal dysfunction? (1) Two formulations of G-PNDJ, lower dose (1.61 wt%) and higher dose (3.14 wt%), five samples each, were eluted in buffered saline under infinite sink conditions. (2) Infections were induced in 16 New Zealand White rabbits by inserting a Kirschner wire in a devascularized radius segment and inoculating with 7.5 × 106 colony-forming units Staphylococcus aureus. At 3 weeks, débridement was performed and a new Kirschner wire was placed in the dead space. Treatment was randomized to higher-dose G-PNDJ or no hydrogel. No systemic antimicrobials were used. Positive culture and acute inflammation on histology were used to determine the presence of infection 4 weeks postdébridement. (3) 3.14 wt% G-PNDJ, 0.75, 1.5, or 3.0 mL, was injected subcutaneously in nine Sprague-Dawley rats, three of each dose. Serum gentamicin, blood urea nitrogen, and creatinine were measured on Days 1, 3, 7, 14, and 28. (1) Gentamicin release was sustained over 7 days with the higher-dose formulation release profile similar to release from high-dose antimicrobial-loaded bone cement. (2) Four weeks postdébridement, infection was present in eight of eight no-hydrogel rabbits but zero of eight rabbits treated with G-PNDJ hydrogel (p < 0.001). (3) Blood urea nitrogen and creatinine were transiently elevated (p < 0.05) only for the two of three rats receiving the 3.0-mL dose on Days 3 and 7. Gentamicin is delivered from PNDJ hydrogel with low systemic exposure and decreased treatment failure for orthopaedic infection. Transient renal dysfunction occurs at high doses. Biodistribution and toxicity testing are needed for G-PNDJ to be clinically usable. Resorbable viscous hydrogels for local antimicrobial delivery may improve outcomes for one-stage management of implant infections when uncemented reconstructions are performed.

31 October 2012 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
DODerek Overstreet
Derek Overstreet
RHRichard Huynh
Richard Huynh
KJKeith Jarbo
Keith Jarbo
RMRyan Y. McLemore
Ryan Y. McLemore
BVBrent Vernon
Brent Vernon

1 July 2013 in Soft Materials
Verified
Journal Article
Closed access
DODerek Overstreet
Derek Overstreet
RMRyan Y. McLemore
Ryan Y. McLemore
BDBrandon D. Doan
Brandon D. Doan
AFAmye Farag
Amye Farag
BVBrent Vernon
Brent Vernon
Temperature-responsive graft copolymers of N-isopropylacrylamide and Jeffamine® M-1000 acrylamide were synthesized to provide controlled swelling without introducing degradable moieties or increasing the LCST above body temperature. Jeffamine® M-1000 caused a small LCST increase (0.24–0.27°C/wt%) and a broader sol-gel transition. Twenty wt% copolymer gels (Mw> 225 kDa) retained their initial volume after 42 days, while homopolymer gels shrank by more than 50%. Copolymer gels eluted 90% within 3 h. These results suggest that Jeffamine® M-1000 acrylamide is suitable for inclusion in N-isopropylacrylamide-based biomaterials to control swelling and drug release nearly independently of LCST.